After failure of first-line VEGFR-TKIs sunitinib or sorafenib in aRCC, look to

CHANGE THEIR COURSE

AFINITOR® (everolimus) Tablets is indicated for the treatment of adults with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

learn more
learn more
 

GET IN TOUCH WITH A SALES REPRESENTATIVE OR REGISTER FOR IMPORTANT UPDATES

learn more

Important Safety Information

  • AFINITOR is contraindicated in patients with hypersensitivity to everolimus, other rapamycin derivatives, or any excipients
  • There have been reports of noninfectious pneumonitis, infections, and renal failure (including acute renal failure) in patients taking AFINITOR, some with fatal outcomes
  • Patients taking concomitant angiotensin-converting enzyme (ACE) inhibitor therapy may be at increased risk for angioedema
  • Oral ulceration is the most frequently occurring adverse event and occurred in 44% to 78% of AFINITOR-treated patients across the clinical trial experience. Most of these events were grade 1/2. Grade 3/4 stomatitis was reported in 4% to 9% of patients
  • Exercise caution with the use of AFINITOR in the perisurgical period, as everolimus delays wound healing and increases the occurrence of wound-related complications
  • Elevations of serum creatinine, proteinuria, glucose, lipids, and triglycerides, and reductions of hemoglobin, lymphocytes, neutrophils, and platelets have also been reported; monitoring of laboratory tests is recommended
  • The use of live vaccines and close contact with those who have received live vaccines should be avoided
  • AFINITOR can cause fetal harm when administered to a pregnant woman

Please see additional Important Safety Information.

Please see full Prescribing Information for AFINITOR.

Abbreviations: aRCC, advanced renal cell carcinoma; mTOR, mammalian target of rapamycin; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor-tyrosine kinase inhibitor.

 

Important Safety Information

AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.

Noninfectious Pneumonitis:

Infections:

Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors:

Oral Ulceration:

Renal Failure:

Impaired Wound Healing:

Laboratory Tests and Monitoring:

Drug-Drug Interactions:

Hepatic Impairment:

Vaccinations:

Embryo-Fetal Toxicity:

Adverse Reactions:

Laboratory Abnormalities:

Please see full Prescribing Information for AFINITOR.